These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Editorial Comment from Dr Satoh to interpreting a rising prostate-specific antigen after brachytherapy for prostate cancer. Satoh T Int J Urol; 2013 Feb; 20(2):149. PubMed ID: 22924812 [No Abstract] [Full Text] [Related]
11. Editorial Comment from Dr Stone to interpreting a rising prostate-specific antigen after brachytherapy for prostate cancer. Stone NN Int J Urol; 2013 Feb; 20(2):148. PubMed ID: 22924786 [No Abstract] [Full Text] [Related]
13. Geographic distribution of prostate cancer incidence in the era of PSA testing, Connecticut, 1984 to 1998. Gregorio DI; Kulldorff M; Sheehan TJ; Samociuk H Urology; 2004 Jan; 63(1):78-82. PubMed ID: 14751353 [TBL] [Abstract][Full Text] [Related]
14. Prostate antigen. A new perception of use in serum. Griffiths J Am J Clin Pathol; 1989 Dec; 92(6):845-6. PubMed ID: 2480063 [No Abstract] [Full Text] [Related]
15. [Do current studies really prove the uselessness of PSA screening? : Attempt at a critical interpretation of the publicized data and the resulting echoes in the media]. Stöckle M Urologe A; 2009 Aug; 48(8):912-6. PubMed ID: 19618157 [No Abstract] [Full Text] [Related]
16. Editorial comment on: Methods of calculating prostate-specific antigen velocity. Eggener S Eur Urol; 2007 Oct; 52(4):1050-1. PubMed ID: 17933029 [No Abstract] [Full Text] [Related]
17. [Statistical study of probabilities of rectal palpation, total PSA, and PSA density in prostate cancer]. Ortiz Cabria R; Adriazola Semino M; Tejeda Bañez E; Alonso Villalba A; García Cobo E; Romero Rodríguez F; Monfá Bosch JM Arch Esp Urol; 2002; 55(1):35-40. PubMed ID: 11957749 [TBL] [Abstract][Full Text] [Related]